Lovelace Biomedical has extensive experience in evaluating medical countermeasures against biological, chemical, radiological and explosive threats, as well as combat casualty care. Lovelace has the ability to work with agents requiring containment and chemical surety (i.e. meets the minimum requirements for AR50-6 Chemical Surety) and CDC select agents in addition to our Nuclear Regulatory Commission (NRC)-approved facilities. We undertake regulated studies in efforts to complete FDA Animal Rule Investigational New Drugs (INDs) leading to full New Drug Application (NDA)/Biologic License Application (BLA) programs.
Our team has developed and validated models of acute radiation syndrome, dermal burn/radiation combinations, and systemic injury models in the gastrointestinal and cardiopulmonary systems, including deep internal expertise in radiation dosimetry, radiation drug countermeasure drug development and risk assessment.